TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Devonian Health Group ( (TSE:GSD) ).
Devonian Health Group has announced advancements in the development of Thykamine™, a therapeutic targeting inflammatory and fibrotic pathways, with ongoing studies in Metabolic Associated Steatohepatitis and pulmonary fibrosis. The company is also exploring oral formulations to expand its market reach. Additionally, Devonian is addressing changes in its product distribution agreements and has corrected the details of a recent private placement, which raised $2,362,999.80.
More about Devonian Health Group
Devonian Health Group Inc. is a clinical stage pharmaceutical company based in Québec, Canada, specializing in the development of drugs for inflammatory autoimmune diseases such as ulcerative colitis and atopic dermatitis. The company also develops cosmeceutical products and operates a commercialization subsidiary, Altius Healthcare Inc., which markets prescription pharmaceutical products in Canada.
Average Trading Volume: 13,594
Technical Sentiment Signal: Sell
Current Market Cap: C$22.97M
Find detailed analytics on GSD stock on TipRanks’ Stock Analysis page.